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Abstract
Background: Antipsychotic prescription information is commonly derived from structured fields in clinical health
records. However, utilising diverse and comprehensive sources of information is especially important when
investigating less frequent patterns of medication prescribing such as antipsychotic polypharmacy (APP). This study
describes and evaluates a novel method of extracting APP data from both structured and free-text fields in
electronic health records (EHRs), and its use for research purposes.
Methods: Using anonymised EHRs, we identified a cohort of patients with serious mental illness (SMI) who were
treated in South London and Maudsley NHS Foundation Trust mental health care services between 1 January and
30 June 2012. Information about antipsychotic co-prescribing was extracted using a combination of natural
language processing and a bespoke algorithm. The validity of the data derived through this process was assessed
against a manually coded gold standard to establish precision and recall. Lastly, we estimated the prevalence and
patterns of antipsychotic polypharmacy.
Results: Individual instances of antipsychotic prescribing were detected with high precision (0.94 to 0.97) and
moderate recall (0.57-0.77). We detected baseline APP (two or more antipsychotics prescribed in any 6-week
window) with 0.92 precision and 0.74 recall and long-term APP (antipsychotic co-prescribing for 6 months) with
0.94 precision and 0.60 recall. Of the 7,201 SMI patients receiving active care during the observation period, 338
(4.7 %; 95 % CI 4.2-5.2) were identified as receiving long-term APP. Two second generation antipsychotics (64.8 %);
and first -second generation antipsychotics were most commonly co-prescribed (32.5 %).
Conclusions: These results suggest that this is a potentially practical tool for identifying polypharmacy from mental
health EHRs on a large scale. Furthermore, extracted data can be used to allow researchers to characterize patterns
of polypharmacy over time including different drug combinations, trends in polypharmacy prescribing, predictors of
polypharmacy prescribing and the impact of polypharmacy on patient outcomes.
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Background
Clinical health records have been previously used to
examine antipsychotic medication prescribing [1, 2];
however, the potential value of electronic health records
(EHRs) remains underexplored. In the context of mental
health care, EHRs contain large volumes of detailed in-
formation in free-text and structured fields, providing an
important resource for conducting analyses using large
samples and investigating a multitude of patient charac-
teristics and outcomes simultaneously [3].
Studies investigating prescription databases [4–6] have
been successful in deriving medication data for large
populations and over long periods of time by predomin-
ately extracting data from structured fields (such as drop
down menus, or dedicated response boxes) [6]. However,
such studies have been restricted by the limited nature
of the derived information [7]. Data on drug prescrip-
tion, as well as related contextual information, is fre-
quently embedded in free-text fields in mental health
EHRs and this may be the only source of such informa-
tion in the absence of e-prescribing or a Primary Care
linkage. Traditionally, extracting free-text information
has necessitated manual coding (where a researcher
reads free-text and codes it by hand according to a de-
fined set of coding rules) [8], which is time and labour
intensive and therefore, not always feasible on a large
scale. This can result in investigating a smaller than ideal
sample [9–12]. EHR text has been analysed automatic-
ally using techniques such as natural language process-
ing (NLP) for a variety of purposes [13]. However,
although this has involved the identification of drugs
[14], as far as we are aware, there have been no attempts
to develop and validate techniques for characterising
meta-data such as polypharmacy.
Automated extraction of information on medication
prescribing is potentially valuable for investigating spe-
cific but important, clinical prescribing patterns such as
the practice of prescribing more than one antipsychotic
drug simultaneously, known as antipsychotic polyphar-
macy (APP), which may be challenging to identify
through manual searches. The prevalence of APP in rou-
tine clinical practice has been estimated to vary between
10-30 % [15] in people with serious mental illness (SMI),
despite little empirical evidence to support benefits asso-
ciated with its use [16], and associations with adverse
health outcomes, such as increased physical health prob-
lems (i.e. weight gain, diabetes, metabolic syndrome,
dyslipidemia) and mortality [17–19]. We need to gain a
better understanding of the clinical characteristics that
predict APP prescribing and determine associated health
outcomes. This information might be provided through
research using the more “real-life” data present in EHRs.
APP is thus an important exposure and potential con-
founder to be considered in studies investigating the
impact of antipsychotic drugs in clinical settings and yet,
as stated, is difficult to characterise on a large scale.
In this paper, we present and evaluate a novel process of
extracting APP data from a large EHR data resource, uti-
lising information available from both structured and free-
text fields. In addition, we were able to use the processed
data to estimate the prevalence of APP, as well as patterns
in co-prescribing, for a six-month period in 2012.
Methods
Settings
South London and Maudsley NHS Foundation Trust
(SLAM) is one of the largest providers of secondary
healthcare in Europe, serving a geographic catchment of
1.23 million residents across four London boroughs
(Lambeth, Southwark, Lewisham and Croydon) [20].
EHRs have been used by SLAM in all its services since
2006. In 2008 The Clinical Record Interactive Search
(CRIS) system was developed [20], which allows re-
searchers to search and retrieve anonymised SLAM
EHRs, with over 230,000 cases currently represented in
the system. CRIS was approval by the Oxfordshire Re-
search Ethics Committee C (reference 08/H606/71).
Sample
All adult service-users with a serious mental illness
(SMI) diagnosis of schizophrenia (ICD-10: F20), schi-
zoaffective disorder (F25) or bipolar disorder (F31) who
received care from SLAM between January and June
2012 were considered. Diagnostic data were derived
from free-text and structured fields within CRIS.
Deriving antipsychotic polypharmacy data from EHRs
All antipsychotic drugs listed in the British National For-
mulary (BNF) 65 were considered. The BNF is a refer-
ence book containing information on pharmacology and
prescribing of many medicines (including 29 antipsy-
chotics) available on the British National Health Service
(NHS). Structured fields for recording medications data
are present in the source EHR interrogated by CRIS, and
were used in this analysis, but these are infrequently
completed. Information was also extracted from SLAM
pharmacy records, although this only covers particular
drugs that are subject to monitoring by the pharmacy
such as clozapine. Most antipsychotic prescription infor-
mation was extracted from free-text fields, including
those recording clinician-patient encounters, and corres-
pondence between healthcare professionals.
We extracted antipsychotic medication data from the
free-text with a NLP information extraction application
developed using General Architecture for Text Engineer-
ing (GATE) software [21], a suite of tools that facilitates
the use and development of NLP applications and fea-
tures. We applied NLP to extract a variety of grammatical
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features, which in turn were used to create specific filters
to maximize precision and recall on instances of anti-
psychotic prescribing. For example, all instances of medi-
cation prescription that were not prescribed at the
‘present time’ (this refers to medication prescribed up
until today, or from today with regard to the date the
document was written) and that did not include a dose
value were excluded at the point of data extraction. There-
fore, any mentions of the drug without such supporting
prescription information were not extracted, as these were
deemed too imprecise.
APP algorithm
Long-term APP was defined as the concomitant use of
two or more antipsychotics for six or more months. We
considered that a concomitant use of antipsychotics for
a six months duration reduces the possibility of misclas-
sifying brief periods of co-prescribing during switching
(a practice known as cross-titration, which typically
takes up to 10 weeks [16, 22]) and ‘as required’ prescrip-
tions as long-term APP; although, our approach cannot
absolutely exclude cross-titration that has taken un-
usually long [16, 23].
APP was ascertained using an algorithm comprising of
two steps, as illustrated by Fig. 1. In step one, case re-
cords were examined to determine whether two or more
antipsychotics were prescribed within a six-week period
between January and June 2012. Co-prescribing at this
stage (t0) was defined as baseline polypharmacy. At
stage two, data on all patients with APP at baseline were
re-examined six months after t0. A manual inspection of
the data revealed that we were initially omitting outpa-
tients who had less frequent clinical appointments and
longer periods of time with no entry in the clinical rec-
ord. Consequently, we specified that the follow-up
search should begin at the point of first clinical event oc-
curring six months or more after t0, which we desig-
nated as t1. Antipsychotic information was extracted
from the clinical records, for the first ten weeks following
t1, to determine whether the same set of antipsychotics
were prescribed; if so, this was classified as ‘long-term’
polypharmacy.
During further development of the algorithm, we
established that NLP-derived time and dose features
were not sufficient to identify cases of APP, as they were
not able to completely exclude historic medication infor-
mation in clinical summaries, resulting in false positive
instances (this refers to cases that are not true polyphar-
macy, but are detected as such by the application).
Therefore, two additional filters were devised, applying
the following exclusions: i) antipsychotic drugs with only
a single annotation (by annotation we mean the identifi-
cation and marking of spans of text that represent the
prescribing of an antipsychotic) for the entire study
period; and ii) antipsychotic drugs with multiple annota-
tions but where all annotations were restricted to a sin-
gle document for the entire study period. We reasoned
that it was unlikely that a patient prescribed particular
medication would have it mentioned in their notes only
once over this period or only on a single day (i.e. a single
document) over this period.
To evaluate the performance of the data extraction
process (NLP application and APP algorithm), we mea-
sured two indicators of validity: precision and recall.
Precision (equivalent to positive predictive value in psy-
chometrics) represents the proportion of patients identi-
fied as polypharmacy considered to be ‘true positive’, out
of all cases identified as such by the algorithm. Recall
(equivalent to sensitivity) represents the proportion of
patients on given medications who were identified as
such by the algorithm.
Validation
Prior to testing the performance of the APP algorithm,
we examined the NLP application on extracting infor-
mation for specific antipsychotic agents prescribed at in-
dividual points in time (i.e. instances rather than
episodes). The first author examined and manually
coded free-text records over a 6-month period (January
to June 2012) for a subset of 120 patients. We chose to
Fig. 1 Antipsychotic polypharmacy algorithm
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examine six frequently prescribed antipsychotics [24]
under the assumption that these medications would have
a larger number of annotations for examination. Preci-
sion and recall for the extraction of clozapine prescrip-
tions using this NLP algorithm is not included here as
this has been described previously [25]. Consequently,
the instances of antipsychotic prescribing varied from
328 to 1150 instances, by antipsychotic agent. We ran
the NLP application over this set of unseen documents
(that had not been used in the development of the NLP
application) and compared the results to our manual
coding of the same dataset.
As illustrated by Fig. 2, the final APP algorithm was
derived following an iterative validation process. From
those that were initially identified as being on polyphar-
macy by the application, we selected a random subset of
40 patients and manually coded their clinical records for
APP, in order to ascertain its ‘true’ occurrence (also re-
ferred to as the ‘gold standard’). The extracted data were
then compared against the gold standard to ascertain
the validity of APP and to examine discrepancies. In-
structions within the algorithm were then added or edi-
ted accordingly until a satisfactory performance was
obtained. To confirm generalizability, the ‘final’ algo-
rithm was tested out on a new subset of 30 randomly se-
lected patients. To estimate recall, from all patients
active in the observation period, we selected a random
subset of 110 individuals.
Analysis
Having assessed the precision and recall of the NLP ap-
plication and APP algorithm, using the APP algorithm
we estimated the prevalence of baseline and long term
(≥6 months) APP. Prevalence estimates and 95 % confi-
dence intervals were reported for baseline and long-term
polypharmacy, as well as for long-term polypharmacy
distribution by antipsychotic class and by individual
agent.
Results
As summarised in Table 1, the NLP application was able
to identify individual instances of the selected anti-
psychotic agents with high precision, although recall
levels were more modest. For the APP algorithm, the
precision obtained from the final validation set of 30 pa-
tients was 0.92 for baseline and 0.94 for long-term APP.
Recall was estimated at 0.74 and 0.60 for baseline and
long- term APP respectively.
We determined that 7,201 adult patients with SMI
diagnosis were active in SLAM services between January
and June 2012. An estimated 830 (11.5 %; 95 % CI 10.8-
12.3) patients were prescribed two or more antipsy-
chotics in any six weeks between January and June 2012,
and 338 (4.7 %; 95 % CI 4.2-5.2) were prescribed the
same set of antipsychotics for six or more months.
Amongst patients prescribed long-term APP, co-
prescribing two or more second-generation antipsy-
chotics (SGAs) was most common (n = 219; 64.8 %; CI
95 % 59.7-69.9), followed by first generation (FGA) and
SGA (n = 110; 32.5 %; CI 95 % 27.5-37.6) combinations,
and two or more FGAs (n = 9; 2.7 %; CI 95 % 0.9-4.4).
Table 2 summarises long-term co-administration pat-
terns by individual agents. Similarly to co-administration
by class, the combination of two (or more) first gener-
ation antipsychotics (FGAs) was relatively rare. The
most common antipsychotic used in combination was
clozapine, combined with at least one other SGA.
Discussion
To our knowledge, this is the first report investigating
the feasibility and yield for a process of extracting APP
data from both structured and free-text fields in EHRs,
using a combination of NLP and a bespoke algorithm.
This process enabled us to identify instances where spe-
cific antipsychotic agents were prescribed, then classify
baseline and long term APP profiles over time.
The NLP application combined with the APP algo-
rithm performed at a high precision, suggesting that in-
dividuals classified as being prescribed APP were very
Fig. 2 Antipsychotic polypharmacy validation process
Table 1 Precision and recall per individual antipsychotic agent
Antipsychotic agent Na Precision (%) Recall (%)
Amisulpride 619 97.4 61.0
Flupentixol 328 94.1 77.0
Haloperidol 747 94.0 57.0
Olanzapine 1150 95.0 69.3
Risperidone 737 95.0 64.1
Zuclopenthixol 390 97.0 67.5
aNumber of annotations per antipsychotic
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likely to be classified correctly. The moderate recall sug-
gested that we were less able to detect all APP cases. In
designing the APP algorithm, we noticed that some of
the rules used to decrease the false positive cases of
APP, filtered out some of the ‘true’ APP cases, requiring
a trade-off decision. Although detecting all cases is desir-
able, especially when investigating relatively uncommon
phenomenon such as polypharmacy, we chose to prioritise
precision over recall due to the large number of non-cases
in the sample, which might be expected to dilute the
impact of any such misclassification in future analyses.
Similarly, the NLP application was developed to favour
precision over recall. In this study we considered date spe-
cific recall when evaluating the NLP application for
extracting individual medications; however, in longitudinal
studies a single patient often has a number of documents
containing the same prescription information, therefore
relatively low recall could be compensated by combining
results extracted from several documents.
We estimated that just under five percent of all adult
patients with SMI were prescribed two or more antipsy-
chotics for six or more months. Although this is com-
parable to some research investigating APP with longer
duration (Morrato et al. [26] found 6.4 % APP preva-
lence in Medicaid population), it is somewhat lower in
comparison to other previous research (10-30 %) [15].
The lower prevalence could be attributable to a more
conservative approach that was adopted in detecting
APP, by examining long-term co-prescription with a
minimum duration of six months. Some previous stud-
ies that have examined concomitant prescribing for 28
days [27], 6 weeks [28, 29] and 60 days [4, 30] may have
included instances of ‘as required’ medication and
switching. It is also possible that some polypharmacy
cases were omitted because we prioritized precision
over recall in developing the NLP application and algo-
rithm. On the other hand, our findings are consistent
with previous research on antipsychotic co-
administration, where two or more SGAs, and FGA-
SGA combinations are found to be the most prevalent
combinations in clinical settings [15, 28, 29, 31, 32].
Previous research has suggested that olanzapine and
risperidone are most commonly combined in co-
prescribing [28, 33], whereas clozapine was the most
commonly co-prescribed antipsychotic in our sample.
Although the therapeutic benefits of clozapine co-
prescribing has been previously called into question [34],
this antipsychotic remains one of few that has some em-
pirical support when used in polypharmacy [35]. Fur-
thermore, most research to date has examined shorter
periods of APP (i.e. 6 weeks) [28], whereas studies inves-
tigating long-term APP have reported a higher preva-
lence of clozapine as a component [4]. Clinically, this
may indicate that patients persistently prescribed APP
over longer periods of time are different from those on
other forms of APP (i.e. short bouts of co-prescribing);
more specifically, it is likely that this sub-group are more
unwell and possibly treatment refractory [36].
Our process of extracting medication data from EHRs
has a number of advantages. For example, in instances
where structured fields are poorly populated or incom-
plete, using supplementary information available in free-
text fields provides more detailed and complete
information of treatments. A particular advantage of
NLP is its ability to take into account the linguistic con-
text around terminology of interest. Therefore, we were
able to identify and exclude negation statements, past
rather than current prescribing, speculations about fu-
ture prescribing and instances in the text where the drug
is mentioned as being taken by a person other than the
patient. Furthermore, the APP algorithm allowed us to
distinguish between different modes of polypharmacy
administration, such as shorter (which would potentially
include ‘as required’ and switching occurrences) and lon-
ger forms of co-prescribing.
Data from EHRs are a source of rich and diverse con-
textual information, much of which may be embedded
Table 2 Prevalence of long-term antipsychotic polypharmacy
combinations (n = 338)
Antipsychotic medication n Plus at least one
other FGAa n (%)
Plus at least one
other SGAa n (%)
First Generation Antipsychotics (FGA)a
Chlorpromazine 8 1 (12.5) 7 (87.5)
Flupentixol 26 6 (23.1) 20 (76.9)
Fluphenazine 4 2 (50.0) 2 (50.0)
Haloperidol 30 5 (16.7) 25 (83.3)
Levomepromazine 1 - 1 (100.0)
Pericyazine 1 1 (100.0) -
Pimozide 2 - 2 (100.0)
Pipothiazine 10 2 (20.0) 8 (80.0)
Sulpride 33 1 (3.0) 32 (97.0)
Trifluoperazine 3 - 3 (100.0)
Zuclopenthixol 25 - 25 (100.0)
Second Generation Antipsychotics (SGA)a
Amisulpride 118 18 (15.3) 100 (84.7)
Aripiprazole 79 12 (15.2) 67 (84.8)
Clozapine 168 27 (16.1) 141 (83.9)
Olanzapine 95 44 (46.3) 51 (53.7)
Paliperidone 40 8 (20.0) 32 (80.0)
Quetiapine 21 11 (52.4) 10 (47.6)
Risperidone 64 21 (32.8) 43 (67.2)
aThese are overlapping categories; antipsychotic combinations may include
additional FGAs or SGA where patients are prescribed more than 2
antipsychotics simultaneously
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in free-text fields. The process described here, may be
adapted to extract an array of factors, which may predict
antipsychotic polypharmacy and/or confound associa-
tions between APP and mental or physical health out-
comes. Routinely collected EHRs capture a range of
populations, such as patients in different clinical settings
(i.e. inpatients/outpatients) and with different socio-
demographic profiles who have been previously been
under-represented and/or under-investigated in research.
Moreover, EHRs more closely approximate real-life clin-
ical practice than formal research projects involving de
novo data collection, permitting the identification of
trends in medication prescribing that are not otherwise
captured by clinical trials. This could be valuable infor-
mation that can be fed back into prescribing guidelines.
Finally, the historic nature of EHRs allows longitudinal
research, where medication profiles can be examined in
relation to multiple predictors and outcomes.
Our current protocol for extracted APP data has a
number of limitations, which should be borne in mind.
As indicated by the recall for individual antipsychotics
and long-term antipsychotic polypharmacy, our ap-
proach may under-estimate the true prevalence of APP.
Furthermore, the output data depends on the quality
and accuracy of clinical entries [20], which may vary by
clinicians and services. Finally, it is important to note
that we examined antipsychotic polypharmacy over a
relatively short period of time, and it is possible that our
data reflects a specific pattern in medication prescribing
during that period.
Conclusions
We have developed a novel process for extracting APP
information from mental health electronic patient re-
cords. We have demonstrated that the combination of
natural language processing and a bespoke algorithm
can be an effective approach to extracting APP data. We
were able to detect APP with high precision and modest
recall. Once extracted these data can be used to allow
researchers to characterize patterns of polypharmacy
over time including different drug combinations, trends
in polypharmacy prescribing, predictors of polypharmacy
prescribing and the impact of polypharmacy on patient
outcomes (such as mortality and physical health conse-
quences). The use of NLP combined with a bespoke al-
gorithm is likely to be applicable to similarly structured
clinical datasets where medications data is held in free-
text. Essentially we have provided an example of an ap-
proach which other researchers may trial in their own
datasets with some modification to suit their specific
needs and source data.
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